NCT03542097View on ClinicalTrials.gov

Assessment of MGMT Promoter Methylation in Advanced Ewing Sarcoma Treated With Temozolomide and Irinotecan

CompletedOBSERVATIONAL
Enrollment

82

Participants

Timeline

Start Date

April 15, 2014

Primary Completion Date

December 31, 2018

Study Completion Date

June 30, 2019

Conditions
Ewing Sarcoma Family of Tumors
Interventions
OTHER

MGMT methylation evaluation

The MGMT methylation will be evaluated by extracting DNA from fresh and Formalin Fixed paraffin Embedded (FFPE) tumor samples

Trial Locations (5)

10060

Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo

10126

Ospedale infantile Regina Margherita, Turin

20133

Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan

40136

Orthopedic Rizzoli Institute, Bologna

SW3 6JJ

The Royal Marsden NHS Foundation Trust, London

All Listed Sponsors
collaborator

Regione Emilia-Romagna

OTHER

lead

Istituto Ortopedico Rizzoli

OTHER

NCT03542097 - Assessment of MGMT Promoter Methylation in Advanced Ewing Sarcoma Treated With Temozolomide and Irinotecan | Biotech Hunter | Biotech Hunter